Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medivir AB ( (SE:MVIR) ) has provided an update.
Medivir AB has received a Notice of Allowance from the Japan Patent Office for its patent application on the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib for treating hepatocellular carcinoma and liver metastases. This patent, which provides protection until April 2041, strengthens Medivir’s strategy to secure clinically relevant combinations in liver cancer and boosts confidence for future patent decisions in other regions.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative cancer treatments, particularly in areas with high unmet medical needs. The company is dedicated to creating drugs that target specific cancer cells while minimizing side effects, with a strong emphasis on collaborations and partnerships. Medivir’s primary focus is on fostroxacitabine bralpamide (fostrox), designed to selectively treat liver cancer cells.
Average Trading Volume: 203,392
Current Market Cap: SEK170.7M
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.